N3 Disease in Esophageal Cancer: Results from a Nationwide Registry
Digestive Surgery · 03.08.2024 · 41 (3) · 133-140
DOI: 10.1159/000540468 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Surgery, online erschienen am 03.08.2024. Verfasst von Charlène J van der Zijden und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Registries, Esophagectomy, Neoplasm Staging. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with extensive lymph node metastases have a poor prognosis. Clinical staging of lymph node metastases poses significant challenges given the limited sensitivity and specificity of imaging techniques. The aim of this study was to investigate the overall survival (OS) of patients with N3 disease in a real-world Dutch population and the added value of surgery in these patients.
Methods
Patients with cN3M0 esophageal or gastroesophageal cancer were identified from the Netherlands Cancer Registry (2012–2019). Treatment consisted of neoadjuvant chemo(radio)therapy followed by resection or chemo(radio)therapy, radiotherapy, or esophagectomy alone. OS was calculated using the Kaplan-Meier method.
Results
Some 21,566 patients were diagnosed with esophageal cancer of whom 359 (1.7%) had cN3M0 disease. Median OS of these patients was 12.5 months (95% CI: 10.7–14.3). Median OS following chemoradiotherapy alone and neoadjuvant therapy plus surgery was 13.3 months (95% CI: 10.7–15.9) and 23.7 months (95% CI: 18.3–29.2), respectively. Of all patients who underwent esophagectomy, 391 (2.8%) had (y)pN3 disease, and median OS was 16.1 months (95% CI: 14.8–17.4). Twenty-one patients (5.4%) were correctly classified as cN3, and 3-year OS was 21%. Conclusion(s): Clinical staging appears to be difficult, apparently in patients with N3 esophageal cancer. Surgery seems to be of benefit to these patients. More research is required to address the ongoing challenges in clinical staging and the best neoadjuvant therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Surgery, Reinier de Graaf Group, Delft, The Netherlands.
- Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Zitieren
APA
van der Zijden, C. J., Olthof, P. B., van der Sluis, P. C., Wijnhoven, B. P. L., Erodotou, M., Hartgrink, H. H., van Etten, B., van Esser, S., Lagarde, S. M., & Dekker, J. W. T. (2024). N3 Disease in Esophageal Cancer: Results from a Nationwide Registry. Digestive Surgery, 41(3), 133-140. https://doi.org/10.1159/000540468
Vancouver
van der Zijden CJ, Olthof PB, van der Sluis PC, Wijnhoven BPL, Erodotou M, Hartgrink HH, et al. N3 Disease in Esophageal Cancer: Results from a Nationwide Registry. Digestive Surgery. 2024;41(3):133-140. doi:10.1159/000540468
BibTeX
@article{vanderZijden2024,
author = {van der Zijden, Charlène J and Olthof, Pim B and van der Sluis, Pieter C and Wijnhoven, Bas P L and Erodotou, Maria and Hartgrink, Henk H and van Etten, Boudewijn and van Esser, Stijn and Lagarde, Sjoerd M and Dekker, Jan Willem T},
title = {N3 Disease in Esophageal Cancer: Results from a Nationwide Registry},
journal = {Digestive Surgery},
year = {2024},
volume = {41},
number = {3},
pages = {133--140},
doi = {10.1159/000540468}
}
EUVIMED